Pazopanib Induced Hand-Foot Skin Reaction

Authors: Ozdemir H , Pektas SD , Alatas ET , Celik SY and Bat B

DOI: 10.23880/cdoaj-16000339

Volume 9, Issue 4

Abstract

Hand-foot syndrome, also known as palmoplantar erythrodysesthesia, palmar-plantar erythema, toxic erythema of the palms and soles, or Burgdorf syndrome, is a common skin reaction to chemotherapeutic agents. In hand-foot syndrome, the palms, soles, dorsal surfaces of the hands and feet, occlusion, friction and pressure areas are affected. Symmetrical erythema and edema are seen on the palms and soles, accompanied by neuropathic pain. It may progress to desquamation, erosion and ulceration with blister formation. The palms are more affected than the soles. The most common causative agents are doxorubicin, liposomal doxorubicin, docetaxel, 5-fluorouracil (5-FU), cytarabine, capecitabine, but it can also be seen due to drugs such as paclitaxel, hydroxyurea, methotrexate, 6-mercaptopurine, cyclophosphamide, cisplatin, daunorubicin, etoposide, vinorelbine, irinotecan and epirubicin. In recent years, with the use of multi-kinase inhibitors in oncology, palmoplantar reactions, which show unique clinical features, have been reported. Pazopanib is a multi-targeted tyrosine kinase inhibitor. It may cause a hand-foot skin reaction with erythematous, hyperkeratotic nodules, bullae and pain and tingling sensation in the hands and feet. If such changes in the hands or feet are observed after starting Pazopanib treatment, the patient should be evaluated for side effects. Treatment should be adjusted if necessary and discontinuation of pazopanib should be considered in severe cases. We present a case of hand-foot skin reaction due to pazopanib.

Keywords: Pazopanib; Hand-Foot Skin Reaction; Drug Side Effects; Skin

View PDF